Adherence to ASCO for Prophylaxis of Acute Chemotherapy- Induced Nausea and Vomiting in Iran

Developing and assessing a vomiting-free ward workflow for gynecological patients receiving chemotherapy

BACKGROUND

Chemotherapy-induced nausea and vomiting (CINV) significantly diminishes the quality of life (QoL) for patients undergoing early and late-stage cancer treatments. Despite preventive antiemetic measures, CINV remains a challenge, with limited response rates. CINV adversely affects not only patients' physical health but also their psychological well-being, social interactions, and treatment adherence.

OBJECTIVE

This study aimed to evaluate the impact of a vomiting-free ward initiative on managing CINV and its effects on the psychological well-being and QoL of gynecological cancer patients receiving chemotherapy.

METHOD

In this study, 960 gynecological oncology patients receiving inpatient chemotherapy at a premier obstetrics and gynecology hospital in Sichuan Province were enrolled from January to December 2023. They were evenly divided into intervention and control groups based on their admission dates. Both groups underwent standard care, and the intervention group followed a vomiting-free ward protocol. The effectiveness of this specialized ward was evaluated using the Multinational Association of Supportive Care in Cancer (MASCC) Antiemesis Tool, the Functional Living Index-Emesis (FLIE), and the Hospital Anxiety and Depression Scale (HADS).

RESULTS

The intervention group showed significant improvements in the frequency and severity of both acute and delayed CINV compared to the control group. Furthermore, there was a 9.7% and 7.2% decrease in the impact of severe nausea and vomiting on leisure activities and a 6.9% and 8.6% reduction in how moderate to severe nausea and vomiting affected daily living, respectively. The introduction of the vomiting-free ward significantly reduced levels of patient anxiety (t = - 3.148, P < 0.001) and depression (t = - 3.223, P < 0.001) compared to standard care.

CONCLUSION

The implementation of a vomiting-free ward effectively mitigates nausea and vomiting, enhances QoL, and decreases anxiety and depression among gynecological oncology patients. This innovative approach can be integrated into clinical practice, providing valuable insights and guidelines for healthcare professionals.

Efficacy of acupoint injection of metoclopramide for post-chemotherapy vomiting: A systematic review and meta-analysis

BACKGROUND

Vomiting is one of the most common adverse events of chemotherapy. The purpose of this study was to systematically review the clinical efficacy of acupoint injection of metoclopramide in the treatment of post-chemotherapy vomiting.

METHODS

We searched 4 general English databases and 4 conventional Chinese databases, all with a time frame from database creation to December 2022. The retrieved clinical trials of acupoint injection of metoclopramide for post-chemotherapy vomiting were then subjected to meta-analysis and trial sequential analysis.

RESULTS

A total of 12 studies were included, with a total sample size of 965 cases. Meta-analysis showed that acupoint injection of metoclopramide was effective in improving anti-vomiting effective rate [odds ratio = 5.67, 95% confidence interval = (3.80,8.47), P < .00001] compared with intramuscular/intravenous injection, and trial sequential analysis showed that this benefit was conclusive. Subgroup analysis demonstrated that acupoint injection significantly improved the anti-vomiting effective rate at doses of 10 mg qd, 20 mg qd, and 30 mg qd, as well as at durations of 1 day and 5 days. Subgroup analysis also indicated that injection at the Zusanli acupoint significantly increased the anti-vomiting effective rate, while injection at the Neiguan acupoint had an anti-vomiting effective rate comparable to that of the control group. Harbord regression showed no significant publication bias (P = .730).

CONCLUSION

Acupoint injection of metoclopramide for post-chemotherapy vomiting is more effective than intramuscular and intravenous injections and is not limited by dose or duration of treatment, which may be the preferred way of administration.

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

• Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics. • The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting. • The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates. • Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade). • All recommendations are for the first course of antineoplastic therapy; modifications may be needed in subsequent courses.

2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential

PURPOSE

Review the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and minimal emetic potential.

METHODS

A working group performed a systematic literature review using Medline, Embase, and Scopus databases between June 2015 and January 2023 of the management of antiemetic prophylaxis for anticancer therapy of low or minimal emetic potential. A consensus committee reviewed recommendations and required a consensus of 67% or greater and a change in outcome of at least 10%.

RESULTS

Of 293 papers identified, 15 had information about managing systemic cancer treatment regimens of low or minimal emetic potential and/or compliance with previous management recommendations. No new evidence was reported that would change the current MASCC recommendations. No antiemetic prophylaxis is recommended for minimal emetic potential therapy, and single agents recommended for low emetic potential chemotherapy for acute emesis, but no prophylaxis is recommended for delayed emesis. Commonly, rescue medication includes antiemetics prescribed for the next higher level of emesis.

CONCLUSION

There is insufficient data to change the current guidelines. Future studies should seek to more accurately determine the risk of emesis with LEC beyond the emetogenicity of the chemotherapy to include patient-related risk assessment.